Skip to main content

Table 4 Associations between tumor and patient characteristics, SNPs, and pCR in breast and lymph nodes

From: Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

     Univariate analysis Multivariate analysis
Parameter   N % pCR OR 95 % CI P value OR 95 % CI P value
Clinical T stage cT1/cT2 106 17.9 1 Reference   1 Reference  
  cT3/T4 73 6.8 0.34 0.12–0.95 0.039 0.49 0.16–1.50 0.209
Clinical N stage cN0 84 21.4 1 Reference   1 Reference  
  cN+ 95 6.3 0.25 0.09–0.66 0.005 0.19 0.06–0.58 0.003
HR status ER+ and/or PR+ 151 8.6 1 Reference   1 Reference  
  Triple negative 28 39.3 6.87 2.66–17.7 0.00007 9.35 3.09–28.3 0.00008
Allocated treatment TAC + ZA 87 14.9 1 Reference 0.559    
TAC only 92 12.0 0.77 0.33–1.83     
Age     0.96 0.89–1.09 0.186    
BMI     0.97 0.88–1.08 0.581    
rs10735380 AA 97 13.4 1 Reference     
IGF1 AG 66 13.6 1.02 0.41–2.55 0.966    
  GG 5 20.0 1.61 0.17–15.6 0.679    
rs1520220 CC 111 15.3 1 Reference     
IGF1 CG 45 13.3 0.85 0.31–2.32 0.752    
  GG 11 0.0    
rs6220 AA 88 11.4 1 Reference     
IGF1 AG 56 16.1 1.49 0.57–3.94 0.418    
  GG 17 17.6 1.67 0.41–6.48 0.475    
rs2270628 CC 101 11.9 1 Reference     
IGFBP3 CT 45 17.8 1.60 0.61–4.24 0.342    
  TT 9 0.0    
rs2854746 GG 55 7.3 1 Reference   1 Reference  
IGFBP3 GC 72 16.7 2.55 0.78–8.40 0.124 3.06 0.82–11.4 0.097
  CC 33 21.2 3.43 0.92–12.8 0.066 4.02 0.92–17.6 0.065
  GG 55 7.3 1 Reference   1 Reference  
  GC/CC 105 18.1 2.82 0.91–8.74 0.073 3.35 0.96–11.7 0.058
rs4320932 TT 106 15.1 1 Reference     
IGF2 TC 57 12.3 0.79 0.30–2.04 0.623    
  CC 8 12.5 0.80 0.09–6.98 0.843    
rs2016347 GG 45 4.4 1 Reference   1 Reference  
IGF1R GT 94 17.0 4.41 0.97–20.1 0.055 5.58 1.08–28.7 0.040
  TT 32 15.6 3.98 0.72–22.0 0.113 6.67 1.03–43.1 0.046
  GG 45 4.4 1 Reference   1 Reference  
  GT/TT 126 16.7 4.30 1.00–19.1 0.056 5.82 1.17–29.1 0.032
  1. BMI body mass index, CI confidence interval, ER estrogen receptor, HR hormone receptor, IGF insulin-like growth factor 1, IGFBP3 insulin-like growth factor binding protein 3, IGF1R insulin-like growth factor 1 receptor, OR odds ratio, pCR pathological complete response, PR progesterone receptor, SNP single nucleotide polymorphism, TAC docetaxel, doxorubicin, cyclophosphamide, ZA zoledronic acid